Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915405 · ClinicalTrials.gov registry record · Phase 1
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
A Phase 1 study, sponsored by Kyowa Kirin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03915405 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin. The registered enrollment target is 16 participants.
The verdict
NCT03915405, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis).
Interventions
- DRUG Avelumab
- DRUG KHK2455
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-09-26 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03915405
The ClinicalTrials.gov registry entry for NCT03915405 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avelumab is the first listed.
NCT03915405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03915405 about?
NCT03915405 is a clinical study titled "KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer". This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis).
What is the current status of trial NCT03915405?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-09-26. Estimated completion is 2022-11-15.
What interventions are being tested in trial NCT03915405?
The interventions under investigation include: Avelumab (DRUG), KHK2455 (DRUG).
Who is sponsoring clinical trial NCT03915405?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.